


PTO/SB/08A		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/997,974
		Filing Date	November 30, 2001
		First Named Inventor	Salvamini
		Confirmation No.	5898
Sheet P E 1	of 5	Attorney Docket No.	MPL 8818-3



RECEIVED

APR 16 2002

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
KCF	1	4,877,561		Iga et al.	10-31-1989
KCF	2	4,999,347		Sorenson	03-12-1991
KCF	3	5,541,174		Sorenson	07-30-1996
KCF	4	5,637,578		Riley et al.	06-10-1997
KCF	5	5,874,421		Riley et al.	06-10-1997

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office	Number ⁴	Kind Code ² (if known)			
KCF	6	CN	1088086	A	Univ Xibei (Uyxi-N)	12-1992	X
KCF	7	EP	0 524 161	A1	Monsanto Company	01-20-1993	
KCF	8	WO	94/15925	A1	Monsanto Company	07-21-1994	
KCF	9	WO	96/39396	A1	Monsanto Company	12-12-1996	
KCF	10	WO	97/33877	A1	Monsanto Company	09-18-1997	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

AUG 14 2002


Examiner Signature	<i>R. R. Donda</i>	Date Considered	12-5-02
--------------------	--------------------	-----------------	---------

TECH CENTER 1600 2900

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



PTO/SB/08A			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	09/997,974
			Filing Date	November 30, 2001
			First Named Inventor	Salvamini
			Confirmation No.	5898
Sheet	2	of	Attorney Docket No.	MPI 83133

Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher and/or country where published.	TECH CENTER 1600/2900
KICF	11	The Merck Index, Twelfth Edition, S. Budavari, editor. Merck & Co., Inc., Whitehouse Station, NJ, 1996 pages 1540-41, monograph 9177.	
KICF	12	BANNISTER, et al., "Aspects of the Structure, Function, and Applications of Superoxide Dismutase." Crit. Rev. Biochem., 1987, Vol. 22(2), 111-180	
KICF	13	BAUEROVA, et al., "Role of Reactive Oxygen and Nitrogen Species in Etiopathogenesis of Rheumatoid Arthrities, Gen. Physiol. Biophys., Vol. 18, 15-20, 1999	
KICF	14	COMHAIR et al., "Rapid Loss of Superoxide Dismutase Activity During Antigen-Induced Asthmatic Responses." Departments of Pulmonary and Critical Care Medicine, and Cancer Biology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195, NO DATE AVAILABLE	
KICF	15	CUZZOCREA, et al., "Beneficial Effects on Tempol, a Membrane-Permeable Radical Scavenger, in a Rodent Model of Collagen-Induced Arthritis." Arthritis & Rheumatism, 2000, Vol. 43, 320-328	
KICF	16	DEL VILLANO, et al., "Elevated Superoxide Dismutase in Black Alcoholics," 1980, (Science, Vol. 207 pp. 991-993	
KICF	17	DE RAEVE et al. "Decreased Cu,Zn-SOD activity in asthmatic airway epithelium: corection by inhaled corticosteroid in vivo." 1997, The american Physiological Society, pp. L148-L154.	
KICF	18	ELMER, et al., "Transgenic Superoxide Dismutase Mice Differ in Opioid-Induced Analgesia," 1995, European Journal of Pharmacology, Vol. 283, pp. 227-232.	
KICF	19	FERRAUDI, "Photochemistry of High-Spin Iron(III) Complexes of the Macrocyclic Ligands [15]pydineN ₅ and [15]pyaneN ₅ . An Investigation of the Charge-Transer Processes." Inorg. Chem., 1980, pp. 438-444, Vol. 19.	
KICF	20	GOLDSTEIN, et al., "Exogenous Gaseous Superoxide Potentiates the Antinociceptive Effect of Opioid Analgesic Agents," 1996, Inflamm Res., Vol. 45, pp. 473-478.	
KICF	21	GRIFFITHS, M.M., et al., "Immunogenetic Control of Experimental Type II Collaen-Induced Arthritis, Arthritis Rheum, 1981, Vol. 2, 781-789	
KICF	22	HARDY, et al., "Superoxide Dismutase Mimetics Inhibit Neutrophil-mediated Human Aortic Endothelial Cell Injury in Vitro, The Journal of Biological Chemistry, 1994, Vol. 269, No. 28, 18535-18540	

Examiner Signature	<i>KRonda</i>	Date Considered	12-5-02
--------------------	---------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

†Unique citation designation number. ‡See attached Kinds of U.S. Patent Documents. §Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ¶For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ¶Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ¶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



PTO/SB/08A		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/997,974
		Filing Date	November 30, 2001
		First Named Inventor	Salvanni
Confirmation No.		5898	RECEIVED APR 16 2002
Sheet	3	of	
APR 18 2002		Attorney Docket No.	MPI 8313.3

GROUP 3600

TECH CENTER 1600/2900

KCF	23	HUBER et al., "Superoxide Dismutase Pharmacology and Orgotein Efficacy: New Perspectives," 1980, Dev. Biochem. Vol. 11B, pp. 395-407.	
KCF	24	KATAOKA, et al., "Hydroxyl Radical Scavenging Activity of Nonsteroidal Anti-Inflammatory Drugs," "Free Rad. Res., 1997, Vol 27(4) 419-427	
KCF	25	KOHÚT, et al., "Effect of Allopurinol and Superoxide Dismutase on Indomethacin-Induced Gastric Lesions in the Rat," 1993, Physiol. Res., Vol. 42. pp. 273-276.	
KCF	26	JOYAVE, et al., "Alteration of Chemically Induced Hepatotoxicity by Copper (II) (3,5-Diisopropylsalicylate) ₂ ," 1985, Biochemical Pharmacology, Vol. 34, No. 21, pp. 3915-3919.	
KCF	27	LENGFELDER, et al., "Superoxide Dismutation by Low Molecular Weight Cu-Complexes," 1981, Bull Europ Physiopath. Resp., Vol. 17 pp. 73-80.	
KCF	28	LI, et al., "Synthesis and Pharmacological Activities of 1,1-Dialkyl-4 (3-Bromopropionyl) Piperazinium Bromides," 1996, Acta Pharmaceutica Sinica, Vol. 31, pp. 757-760.	
KCF	29	LIN, et al., "Use of Superoxide Dismutase (SOD) in Patients with Temporomandibular Joint Dysfunction - a Preliminary Study," 1994, Int. J. Oral Maxillofac. Surg., Vol. 23, pp. 428-429	
KCF	30	LLESUY et al., "Oxidative Stress in Muscle and Liver of Rats with Septic Syndrome" Free Radical Biology & Medicine, Vol. 16, No. 4, 445-451, 1994	
KCF	31	MACARTHUR, et al., "Inactivation of Catecholamines by Superoxide Gives New Insights on the Pathogenesis of Septic Shock." PNAS, 2000, Vol 97(17), 9753-9758	
KCF	32	MAO, et al., "Mechanisms of hyperalgesia and Morphine tolerance: a current view of their possible interactions," 1995, Pain, Vol. 62, pp. 359-274.	
KCF	33	MATTEY, et al., "Influence of Polymorphism in the Manganese Superoxide Dismutase Locus on Disease Outcome in Rheumatoid Arthritis" Arthritis & Rheumatism, 2000, 859-864, Vol. 43.	
KCF	34	McCord, "Superoxide Dismutase: Rationale for Use in Reperfusion Injury and Inflammation." Journal of Free Radicals in Biology & Medicine, 1986, Vol 2, 307-310	
KCF	35	MERTENS, et al., "Study of eosinophil-endothelial adhesion, production of oxygen radicals and release of eosinophil cationic protein by peripheral blood eosinophils of patients with rheumatoid arthritis" Clinical and Experimental Allergy, Vol. 23 868-873. (1993)	
KCF	36	"Modified Superoxide Dismutase as Inflammation Inhibitor and Others," 1989, (Chemical Abstracts Vol. 111, No. 15) p.353.	


RECEIVED

Examiner Signature	<i>R. R. Orde</i>	Date Considered	12-5-02	AUG 14 2002
--------------------	-------------------	-----------------	---------	-------------


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	09/997,974
		Filing Date	November 30, 2001
		First Named Inventor	Salvamani
RECEIVED APR 18 2002		Confirmation No.	5898
		Attorney Docket No.	MPI 831331 6 2002
Sheet	4	of	

GROUP 3600				TECH CENTER 1600/2900	
KCF	37	OKUYAMA, et al., "Copper Complexes of Non-steroidal Antiinflammatory agents: Analgesic Activity and Possible Opioid Receptor Activation,," 1987, Agents and Actions, Vol. 21,1/2, pp. 130-144.			
KCF	38	ORVISKY, et al., "High-Molecular-Weight Hyaluronan--a Valuable tool in Testing the Antioxidative Activity of Amphiphilic Drugs Stobadine and Vinpocetine." Journal of Pharmaceutical and Biomedical Analysis, 1997, Vol 16, 419-424			
KCF	39	PARFITT, et al., "Bone Histomorphometry: Standarization of Nomenclature, Symbols, and Units." Journal of Bone and Mineral Research, 1987, Vol 2, 595-610			
KCF	40	PETKAU, "Scientific Basis for the Clinical Use of Superoxide Dismutase." Cancer Treatment Reviews, 1986, Vol 13, 17-44			
KCF	41	RAKOWSKI et al., "Synthesis and Characterization of Transition Metal Complexes Containing a Pentadentate Macrocyclic Ligand." Inorganic Chemistry, 1975, pp. 1194-1200, Vol. 14, No. 5.			
KCF	42	RILEY et al., "Rational Design of Synthetic Enzymes and Their Potential Utility as Human Pharmaceuticals" CatTech, I, 41, 1997			
KCF	43	RILEY et al., "Stopped-Flow Kinetic Analysis for Monitoring Superoxide Decay in Aqueous Systems, Analytical Biochemistry, Vol., 196, 344-349, 1991			
KCF	44	RILEY et al., "Synthesis, Characterization, and Stability of Manganese (II) C-Substituted 1,4,7,10,13-Pentaazacyclopentadecane Complexes Exhibiting Superoxide Dismutase Activity." Inorg. Chem, 1996, pp. 5213-5231, Vol. 35.			
KCF	45	SALVEMINI et al., "A Nonpeptidyl Mimic of Superoxide Dismutase with Therapeutic Activity in Rats." Science, 1999, pp. 304-306, Vol. 286.			
KCF	46	SHUFF, et al., "Stable Superoxide Dismutase (SOD)-Mimetic Ternary Human Serum Albumin-Cu(II)(3,5-Diisopropylsalicylate), Complexes in Tissue Distribution of the Binary Complex," 1992, Biochemical Pharmacology, Vol. 43, No. 7, pp. 1601-1612.			
KCF	47	M. TAL, "A Novel Antioxidant Alleviates heat Hyperalgesia in Rats with an Experimental Painful Peripheral Neuropathy," 1996, NeuroReport, Vol. 7, pp. 1382-1384			
KCF	48	TAWARA, T., et al., "Effects of Recombinant Human IL-1 b on Production of Prostaglandin E2, Leukotriene B4, NAG, and Superoxide by Human Synovial Cells and Chondrocytes" Inflammation, 1991, Vol. 15, No. 2, 145-157			
KCF	49	TAYLOR, et al., "Oxidative Metabolism in Sepsis and Sepsis Syndrome" Journal of Critical Care, 1995, Vol. 10, No. 3, 122-135			

Examiner Signature		Date Considered	12-5-02
		RECEIVED AUG 14 2002	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



PTO/SB/08A

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/997,974
Filing Date	November 30, 2001
First Named Inventor	Varsano
Confirmation No.	5898
Attorney Docket No.	MPI 8313.3

Sheet

5

of

5

GROUP 3600

TECH CENTER 1600/2900

KKF	50	TIKU, et al., "Evidence Linking Chondrocyte Lipid Peroxidation to Cartilage Matrix Protein Degradation" J. Biol. Chem, 2000, 20069-20076, Vol. 275.	
KKF	51	VARSANO, et al., "Superoxide Dismutase Activity in Morphine- and Meperidine- Addicted Mice and Their Response to Paraquat Poisoning," 1992, (FEBS) pp. S54-S59.	
KKF	52	WATSON, et al., "Human HLA-DR β Gene Hypervariable Region Homology in the BioBreeding BB Rat: Selection of the Diabetic-resistant Subline as a Rheumatoid Arthritis Research Tool to Characterize the Immunopathologic Response to Human Type II Collagen, J. Exp. Med., 1990, Vol. 172, 1331-1339	
KKF	53	WEISS, R.H., et al., "Maganese-Based Superoxide Dismutase Mimics: Design, Discovery and Pharmacologic Efficacies" The Oxygen Paradox, Davies, K.J.A., and Ursini, F., Eds. pp. 641-651, CLEUP University Press, Padova, Italy	
KKF	54	WEISS, R. H., et al., "Maganese-based Superoxide Dismutase Mimetics Inhibit Neutrophil Infiltration <i>in Vivo</i> ," The Journal of Biological Chemistry, Vol. 271, No. 42, 26149-26156, 1996	
KKF	55	WEISS, R. H., et al., "Maganese (II) - Based Superoxide Dismutase Mimetics: Rational Drug Design of Artificial Enzymes" Drugs of the Future, 21, 383-389, 1996	
KKF	56	WEISS, R. H., et al., "Keystone Symposia on the Molecular Basis of Oxidative Damage by Leukocytes." J. Cell. Biochem., 1991, Suppl. 15C, 216	
KKF	57	WEISS, R.H., et al., "Therapeutic Aspects of Manganese(II)-based Superoxide Dismutase Mimics." Inorganic Chemistry in Medicine, (Farrell, N., Ed.), Royal Society of Chemistry	
KKF	58	WEISS, R.H., et al., "Evaluation of Activity of Putative Superoxide Dismutase Mimics." Journal of Biological Chemistry, 1993, Vol. 268(31), 23049-23054	

RECEIVED

AUG 14 2002

TECH CENTER 1600/2900

Examiner Signature	<i>RR Dinda</i>	Date Considered	12-5-02
-----------------------	-----------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.